PE20180036A1 - Inhibidores de bromodominio - Google Patents
Inhibidores de bromodominioInfo
- Publication number
- PE20180036A1 PE20180036A1 PE2017002306A PE2017002306A PE20180036A1 PE 20180036 A1 PE20180036 A1 PE 20180036A1 PE 2017002306 A PE2017002306 A PE 2017002306A PE 2017002306 A PE2017002306 A PE 2017002306A PE 20180036 A1 PE20180036 A1 PE 20180036A1
- Authority
- PE
- Peru
- Prior art keywords
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- pharmaceutical composition
- bromodominium
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- UWZAJPITKGWMFJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Chemical compound Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O UWZAJPITKGWMFJ-UHFFFAOYSA-N 0.000 abstract 3
- 229920000642 polymer Polymers 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000010922 spray-dried dispersion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Referida a una composicion farmaceutica que comprende la forma cristalina A de 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona. En algunas realizaciones, la composicion farmaceutica comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona que se ha procesado por micronizacion o dispersion secada por pulverizacion. En algunas realizaciones, la composicion farmaceutica comprende ademas al menos un polimero. En algunas realizaciones, las composiciones farmaceuticas comprenden una matriz polimerica solida que comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona y al menos un polimero. Dichas composiciones farmaceuticas son utiles para el tratamiento del cancer o enfermedades neoplasicas
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180036A1 true PE20180036A1 (es) | 2018-01-09 |
Family
ID=57143581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002306A PE20180036A1 (es) | 2015-04-22 | 2016-04-22 | Inhibidores de bromodominio |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (es) |
| EP (1) | EP3285770A4 (es) |
| JP (1) | JP2018513863A (es) |
| KR (1) | KR20170139119A (es) |
| CN (1) | CN107613981A (es) |
| AR (1) | AR104340A1 (es) |
| AU (1) | AU2016252992A1 (es) |
| BR (1) | BR112017022691A2 (es) |
| CA (1) | CA2983446C (es) |
| CL (1) | CL2017002679A1 (es) |
| CO (1) | CO2017011482A2 (es) |
| EA (1) | EA201792317A1 (es) |
| EC (1) | ECSP17071545A (es) |
| HK (1) | HK1243948A1 (es) |
| IL (1) | IL255120B (es) |
| MX (2) | MX390077B (es) |
| PE (1) | PE20180036A1 (es) |
| PH (1) | PH12017501933A1 (es) |
| SG (1) | SG11201708627TA (es) |
| TW (1) | TW201642860A (es) |
| WO (1) | WO2016172618A1 (es) |
| ZA (1) | ZA201707186B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3528810A4 (en) * | 2016-10-20 | 2020-06-17 | Celgene Quanticel Research, Inc. | BROMDOMAIN INHIBITOR |
| EP3532059B1 (en) | 2016-10-27 | 2022-01-26 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
| US11566004B2 (en) * | 2018-07-23 | 2023-01-31 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
| EP4294397A1 (en) * | 2021-02-22 | 2023-12-27 | Celgene Quanticel Research, Inc. | Bromodomain (bet) inhibitor for use in treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP3640241B1 (en) * | 2013-10-18 | 2022-09-28 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
| EP3528810A4 (en) * | 2016-10-20 | 2020-06-17 | Celgene Quanticel Research, Inc. | BROMDOMAIN INHIBITOR |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL255120A0 (en) | 2017-12-31 |
| CA2983446A1 (en) | 2016-10-27 |
| KR20170139119A (ko) | 2017-12-18 |
| HK1243948A1 (zh) | 2018-07-27 |
| JP2018513863A (ja) | 2018-05-31 |
| TW201642860A (zh) | 2016-12-16 |
| MX2017013501A (es) | 2018-02-09 |
| EP3285770A4 (en) | 2018-10-31 |
| AU2016252992A1 (en) | 2017-11-09 |
| ZA201707186B (en) | 2019-01-30 |
| SG11201708627TA (en) | 2017-11-29 |
| US20160310423A1 (en) | 2016-10-27 |
| CO2017011482A2 (es) | 2018-01-31 |
| CL2017002679A1 (es) | 2018-05-25 |
| WO2016172618A1 (en) | 2016-10-27 |
| MX377159B (es) | 2025-03-07 |
| CA2983446C (en) | 2024-04-09 |
| MX390077B (es) | 2025-03-20 |
| EA201792317A1 (ru) | 2018-03-30 |
| ECSP17071545A (es) | 2017-12-01 |
| AR104340A1 (es) | 2017-07-12 |
| BR112017022691A2 (pt) | 2018-07-17 |
| MX2020010899A (es) | 2022-02-15 |
| NZ736630A (en) | 2024-03-22 |
| IL255120B (en) | 2021-03-25 |
| CN107613981A (zh) | 2018-01-19 |
| PH12017501933A1 (en) | 2018-03-19 |
| EP3285770A1 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180036A1 (es) | Inhibidores de bromodominio | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CL2018001230A1 (es) | Tratamiento de osteoartritis | |
| CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
| MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| AR102657A1 (es) | Composición para tratar telas | |
| MX384264B (es) | Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| MX2014005342A (es) | Inhibidores del virus de la hepatitis c. | |
| BR112017003705A2 (pt) | compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea | |
| MX2018003497A (es) | Formulaciones de aminoacidos de liberacion modificada administradas por via oral. | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| PE20171646A1 (es) | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| BR112016017776A2 (pt) | Formas sólidas de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, composições das mesmas e métodos para seu uso | |
| MX2017005064A (es) | Metodos para tratar afecciones oculares. | |
| BR112018009745A2 (pt) | compostos heterocíclicos para o tratamento de doença | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| PE20170313A1 (es) | Formulacion de ceritinib | |
| BR112017028185A2 (pt) | composições farmacêuticas sólidas para tratar hcv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |